Related Experiment Videos

Roundtable discussion: Electrolytes in cardiovascular disease and hypertension

Marvin Moser¹, Jan Basile, Domenic Sica

¹Yale University School of Medicine, New Haven, CT, USA.

Journal of Clinical Hypertension (Greenwich, Conn.)

|December 23, 2003

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

The New England journal of medicine·2025

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.

Hypertension research : official journal of the Japanese Society of Hypertension·2024

Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.

Circulation·2023

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.

American heart journal·2023

General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial.

Cardiovascular diabetology·2023

Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials.

JAMA cardiology·2023

See all related articles